
CMFT NHS TRUST
CMFT NHS TRUST
3 Projects, page 1 of 1
Open Access Mandate for Publications and Research data assignment_turned_in Project2018 - 2024Partners:EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION, FUNDACIO CENTRE DE REGULACIO GENOMICA, EMBL, Charles University, AP-HP +22 partnersEURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION,FUNDACIO CENTRE DE REGULACIO GENOMICA,EMBL,Charles University,AP-HP,STICHTING RADBOUD UNIVERSITEIT,THE JACKSON LABORATORY NON PROFIT CORPORATION,Universitäts-Augenklinik Bonn,CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO,UCL,Charité - University Medicine Berlin,CMFT NHS TRUST,MANCHESTER UNIVERSITY NHS FOUNDATION TRUST,IPATIMUP - INSTITUTO DE PATOLOGIA EIMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP,University of Campania "Luigi Vanvitelli",Newcastle University,KCL,uB,Centre Hospitalier Universitaire Dijon Bourgogne,University of Leicester,SHU,University of Tübingen,University of Ferrara,UAntwerpen,UMCG,INSERM,RADBOUDUMCFunder: European Commission Project Code: 779257Overall Budget: 15,361,600 EURFunder Contribution: 15,361,600 EURThe main ambitions of the Solve-RD proposal are (i) to solve large numbers of RD, for which a molecular cause is not known yet, by sophisticated combined Omics approaches, and (ii) to improve diagnostics of RD patients through a “genetic knowledge web”. Solve-RD will pursue a clear visionary and integrated “beyond the exome” approach. The entire Solve-RD proposal has been motivated, designed and put together by a core group of four ERNs, but also reaches out to all 24 ERNs. To tackle diseases which are unsolved by applying cutting edge strategies, Solve-RD has thus formed a consortium that comprises (i) leading clinicians, geneticists and translational researchers of these ERNs, (ii) RD research and diagnostic infrastructures, (iii) patient organisations, as well as (iv) leading experts in the field of -omics technologies, bioinformatics and knowledge management. Solve-RD will deliver 7 main implementation steps: (i) Collect Phenotypes, (ii) New phenotype patterns, (iii) Re-analyse exomes / genomes, (iv) Novel molecular strategies, (v) Functional analysis, (iv) Clinical utility and (vii) Towards therapy. For analysis Solve-RD will apply data driven and expert driven approaches. We anticipate to increase diagnostic yield from 19.000 unsolved exomes/genomes by about 3-5%. Cohort specific innovative -omis strategies will be pursued, also addressing cost-effective issues. Analysis of more than 800 patients with highly peculiar (ultra-rare) phenotypes will highly increase the chance to find novel disease genes and novel disease mechanisms. We anticipate to solve more than 2.000 cases. Finding further matching patients will be secured by newly developed matchmaking approaches and by screening using MIPs technology in the more than 20.000 unclassified patients of the ERNs. For the first time in Europe we will also implement a novel brokerage structure connecting clinicians, gene discoverer and basic researcher to quickly verify novel genes and disease mechanisms.
more_vert assignment_turned_in Project2012 - 2017Partners:ESTAV CENTRO, TEKNOLOGIAN TUTKIMUSKESKUS VTT OY, BAXI PARTNERSHIP LIMITED, AQUAS, CMFT NHS TRUST +8 partnersESTAV CENTRO,TEKNOLOGIAN TUTKIMUSKESKUS VTT OY,BAXI PARTNERSHIP LIMITED,AQUAS,CMFT NHS TRUST,TICSALUT,AQUAS,ANCI INNOVAZIONE S.R.L,BDigital,FSHS,HELSINKI REGION CENTER OF EXPERTISE UUDENMAAN OSAA,EURECAT,ESTARFunder: European Commission Project Code: 288028more_vert Open Access Mandate for Publications assignment_turned_in Project2013 - 2015Partners:Salisbury NHS Foundation Trust, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, University of Manchester, STICHTING RADBOUD UNIVERSITEIT, UoA +6 partnersSalisbury NHS Foundation Trust,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,University of Manchester,STICHTING RADBOUD UNIVERSITEIT,UoA,KUL,GENOMIC INVESTMENTS BV,LUMC,Newcastle University,CMFT NHS TRUST,CARTAGENIAFunder: European Commission Project Code: 602269more_vert